A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

NCT00113490 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

NCT03636906 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy

NCT06647654 ·Status: ACTIVE_NOT_RECRUITING

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

NCT02534935 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

NCT00538785 ·Status: COMPLETED ·Phase: PHASE2

Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

NCT05193279 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

NCT00798304 ·Status: TERMINATED ·Phase: PHASE2

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age

NCT02890381 ·Status: TERMINATED ·Phase: PHASE1

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

NCT03333317 ·Status: TERMINATED ·Phase: PHASE2

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

NCT00316264 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

NCT03606512 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

NeisVac-C Single Prime Study in Infants

NCT01218451 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

NCT01214837 ·Status: COMPLETED ·Phase: PHASE3

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

NCT01768117 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®

NCT01054053 ·Status: COMPLETED

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

NCT00381615 ·Status: COMPLETED ·Phase: PHASE2

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

NCT04919109 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe Gastroenteritis

NCT01978223 ·Status: WITHDRAWN

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

NCT07222384 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)

NCT01621945 ·Status: COMPLETED

Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)

NCT06646744 ·Status: COMPLETED

A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

NCT05436834 ·Status: COMPLETED ·Phase: PHASE3

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

NCT00879814 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of BLIS K12 as Preventive Measure for Rheumatic Children

NCT02407106 ·Status: UNKNOWN ·Phase: NA